Prostate cancer therapy has seen radical changes and improvements recently, with a multitude of clinical trials currently underway. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France, briefly mentions the current therapies available before talking about promising new avenues being explored. Prof. Fizazi covers a range of therapetic targets, including PSMA, which can be be targeted using radioactive isotope-labeled ligands.
The future of prostate cancer therapy
